Payment overview · 2025
General Payments
$5,321.82
132 reported records · 23 companies
Healthcare provider profile · identity verified
Robert W Heidepriem, MD
Allopathic & Osteopathic Physicians|Surgery|Vascular Surgery · COLUMBUS, GA · NPI 1619959673
Verified facts
What the public records show
CMS Open Payments records show Robert W Heidepriem, MD received $5,321.82 in general payments during 2025 across 132 reported records.
Boston Scientific Corporation accounted for 25.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 55 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $1,364.17 | 25.6% | 39 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $956.17 | 18.0% | 29 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $687.23 | 12.9% | 14 | 2025 |
| Bolton Medical Inc | Unresolved — no canonical attribution shown | $488.71 | 9.2% | 7 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $475.83 | 8.9% | 6 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $251.20 | 4.7% | 3 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $212.42 | 4.0% | 5 | 2025 |
| LeMaitre Vascular, Inc. | Unresolved — no canonical attribution shown | $149.55 | 2.8% | 2 | 2025 |
| Veryan Medical Incorporated | Unresolved — no canonical attribution shown | $123.04 | 2.3% | 1 | 2025 |
| Cagent Vascular INC | Unresolved — no canonical attribution shown | $98.98 | 1.9% | 2 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $84.84 | 1.6% | 5 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $64.00 | 1.2% | 1 | 2025 |
| Solventum Corporation | Unresolved — no canonical attribution shown | $55.30 | 1.0% | 2 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $48.45 | 0.9% | 3 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $45.50 | 0.8% | 2 | 2025 |
| Ethicon US, LLC | Unresolved — no canonical attribution shown | $40.67 | 0.8% | 2 | 2025 |
| Surmodics, Inc. | Unresolved — no canonical attribution shown | $35.81 | 0.7% | 2 | 2025 |
| Imperative Care, Inc | Unresolved — no canonical attribution shown | $34.00 | 0.6% | 2 | 2025 |
| ETS Wound Care LLC | Unresolved — no canonical attribution shown | $33.12 | 0.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $22.31 | 0.4% | 1 | 2025 |
| Urgo Medical North America, LLC | Unresolved — no canonical attribution shown | $19.32 | 0.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.05 | 0.3% | 1 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $15.15 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $5,321.82 | 132 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $934.46 | 28 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $687.23 | 14 | 2025 |
Source payment records
|
|||||
| TREO ABDOMINAL STENT-GRAFT SYSTEM Normalized: treo abdominal stent graft system |
Device | Bolton Medical Inc | $488.71 | 7 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $475.83 | 6 | 2025 |
Source payment records
|
|||||
| ENROUTE Transcarotid Neuroprotection System Normalized: enroute transcarotid neuroprotection system |
Device | Boston Scientific Corporation | $435.72 | 10 | 2025 |
Source payment records
|
|||||
| ELUVIA Normalized: eluvia |
Device | Boston Scientific Corporation | $283.48 | 5 | 2025 |
Source payment records
|
|||||
| ARTEGRAFT VASCULAR GRAFT Normalized: artegraft vascular graft |
Device | LeMaitre Vascular, Inc. | $149.55 | 2 | 2025 |
Source payment records
|
|||||
| LIMFLOW SYSTEM Normalized: limflow system |
Device | Stryker Corporation | $139.58 | 1 | 2025 |
Source payment records
|
|||||
| General - Angioplasty Normalized: general angioplasty |
Device | Boston Scientific Corporation | $127.83 | 1 | 2025 |
Source payment records
|
|||||
| BioMimics 3D Vascular Stent System Normalized: biomimics 3d vascular stent system |
Device | Veryan Medical Incorporated | $123.04 | 1 | 2025 |
Source payment records
|
|||||
| ENDOCROSS Device Normalized: endocross device |
Device | Endologix LLC | $122.54 | 1 | 2025 |
Source payment records
|
|||||
| Torus Stent Graft System Normalized: torus stent graft system |
Device | Endologix LLC | $122.54 | 1 | 2025 |
Source payment records
|
|||||
| Serrantor Normalized: serrantor |
Device | Cagent Vascular INC | $98.98 | 2 | 2025 |
Source payment records
|
|||||
| ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter Normalized: enroute enflate transcarotid rx balloon dilatation catheter |
Device | Boston Scientific Corporation | $96.14 | 1 | 2025 |
Source payment records
|
|||||
| EkoSonic Normalized: ekosonic |
Device | Boston Scientific Corporation | $82.77 | 4 | 2025 |
Source payment records
|
|||||
| GORE TAG Conformable Thoracic Endoprosthesis Normalized: gore tag conformable thoracic endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $64.00 | 1 | 2025 |
Source payment records
|
|||||
| Ranger Normalized: ranger |
Device | Boston Scientific Corporation | $55.39 | 3 | 2025 |
Source payment records
|
|||||
| PREVENA Normalized: prevena |
Device | Solventum Corporation | $55.30 | 2 | 2025 |
Source payment records
|
|||||
| General - Vascular Intervention Normalized: general vascular intervention |
Device | Boston Scientific Corporation | $53.90 | 3 | 2025 |
Source payment records
|
|||||
| APLIGRAF Normalized: apligraf |
Device | Organogenesis Inc. | $52.24 | 3 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $48.45 | 3 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $48.45 | 3 | 2025 |
Source payment records
|
|||||
| Express LD Iliac / Biliary Normalized: express ld iliac biliary |
Device | Boston Scientific Corporation | $45.85 | 2 | 2025 |
Source payment records
|
|||||
| RELAY THORACIC STENT-GRAFT WITH PLUS DELIVERY SYSTEM Normalized: relay thoracic stent graft with plus delivery system |
Device | Bolton Medical Inc | $45.38 | 2 | 2025 |
Source payment records
|
|||||
| ETHICON Normalized: ethicon |
Device | Ethicon US, LLC | $40.67 | 2 | 2025 |
Source payment records
|
|||||
| PROLENE Normalized: prolene |
Device | Ethicon US, LLC | $40.67 | 2 | 2025 |
Source payment records
|
|||||
| VISTASEAL Normalized: vistaseal |
Biological | Ethicon US, LLC | $40.67 | 2 | 2025 |
Source payment records
|
|||||
| General - Thrombectomy Normalized: general thrombectomy |
Device | Boston Scientific Corporation | $38.54 | 2 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $36.48 | 2 | 2025 |
Source payment records
|
|||||
| ARTIX MT Normalized: artix mt |
Device | Stryker Corporation | $36.36 | 2 | 2025 |
Source payment records
|
|||||
| Pounce Thrombectomy Normalized: pounce thrombectomy |
Device | Surmodics, Inc. | $35.81 | 2 | 2025 |
Source payment records
|
|||||
| MIRRAGEN ADVANCED WOUND MATRIX Normalized: mirragen advanced wound matrix |
Device | ETS Wound Care LLC | $33.12 | 1 | 2025 |
Source payment records
|
|||||
| PURAPLY WOUND MATRIX Normalized: puraply wound matrix |
Device | Organogenesis Inc. | $32.60 | 2 | 2025 |
Source payment records
|
|||||
| GRAFIX PL Normalized: grafix pl |
Biological | Smith+Nephew, Inc. | $27.58 | 1 | 2025 |
Source payment records
|
|||||
| STRAVIX Normalized: stravix |
Biological | Smith+Nephew, Inc. | $27.58 | 1 | 2025 |
Source payment records
|
|||||
| Epic Vascular Normalized: epic vascular |
Device | Boston Scientific Corporation | $24.74 | 1 | 2025 |
Source payment records
|
|||||
| OptiCross 35 Normalized: opticross 35 |
Device | Boston Scientific Corporation | $23.64 | 1 | 2025 |
Source payment records
|
|||||
| General - Angiography Normalized: general angiography |
Device | Boston Scientific Corporation | $22.55 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $22.31 | 1 | 2025 |
Source payment records
|
|||||
| RUBY Coil Normalized: ruby coil |
Device | Penumbra, Inc. | $21.71 | 1 | 2025 |
Source payment records
|
|||||
| JETSTREAM SC Normalized: jetstream sc |
Device | Boston Scientific Corporation | $21.37 | 1 | 2025 |
Source payment records
|
|||||
| SURGICEL NU-KNIT Normalized: surgicel nu knit |
Device | Ethicon US, LLC | $20.96 | 1 | 2025 |
Source payment records
|
|||||
| General - Balloons Normalized: general balloons |
Device | Boston Scientific Corporation | $19.83 | 1 | 2025 |
Source payment records
|
|||||
| STRATAFIX Normalized: stratafix |
Device | Ethicon US, LLC | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| VASHE WOUND SOLUTION 250 ML (8.5 FL OZ) FLIP TOP CAP Normalized: vashe wound solution 250 ml 8 5 fl oz flip top cap |
Device | Urgo Medical North America, LLC | $19.32 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $17.92 | 1 | 2025 |
Source payment records
|
|||||
| PRODIGY CATHETER Normalized: prodigy catheter |
Device | Imperative Care, Inc | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| SYMPHONY CATHETER Normalized: symphony catheter |
Device | Imperative Care, Inc | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $16.05 | 1 | 2025 |
Source payment records
|
|||||
| V.A.C. VERAFLO CLEANSE CHOICE Normalized: v a c veraflo cleanse choice |
Device | Solventum Corporation | $15.91 | 1 | 2025 |
Source payment records
|
|||||
| AngioJet Ultra 5000A Normalized: angiojet ultra 5000a |
Device | Boston Scientific Corporation | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $15.15 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $15.15 | 1 | 2025 |
Source payment records
|
|||||
| General - Guidewires Normalized: general guidewires |
Device | Boston Scientific Corporation | $10.56 | 1 | 2025 |
Source payment records
|
|||||
| Innova Vascular Normalized: innova vascular |
Device | Boston Scientific Corporation | $6.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 174 | 68 |
| Cilostazol | Cilostazol | 173 | 40 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 152 | 106 |
| Xarelto | Rivaroxaban | 79 | 21 |
| Cephalexin | Cephalexin | 49 | 34 |
| Pentoxifylline | Pentoxifylline | 37 | suppressed |
| Eliquis | Apixaban | 34 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 32 | 11 |
| Tramadol Hcl | Tramadol Hcl | 25 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 19 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 11 |
| Gabapentin | Gabapentin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $5,321.82 · 132 records | Boston Scientific Corporation | APLIGRAF, ARTEGRAFT VASCULAR GRAFT, ARTIX MT, AngioJet Ultra 5000A, Barostim Neo System, BioMimics 3D Vascular Stent System, CLOTTRIEVER BOLD CATHETER, COLLAGENASE SANTYL, ELUVIA, ENDOCROSS Device, ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter, ENROUTE Transcarotid Neuroprotection System, ESPRIT, ETHICON, EkoSonic, Epic Vascular, Express LD Iliac / Biliary, Flexitouch Plus, GORE TAG Conformable Thoracic Endoprosthesis, GRAFIX PL, General - Angiography, General - Angioplasty, General - Balloons, General - Guidewires, General - Thrombectomy, General - Vascular Intervention, Indigo System, Innova Vascular, JETSTREAM SC, Kerecis GraftGuide, Kerecis SurgiClose, LIMFLOW SYSTEM, MIRRAGEN ADVANCED WOUND MATRIX, Nimbl, OptiCross 35, PREVENA, PRODIGY CATHETER, PROLENE, PURAPLY WOUND MATRIX, Pounce Thrombectomy, QULIPTA, RELAY THORACIC STENT-GRAFT WITH PLUS DELIVERY SYSTEM, RUBY Coil, Ranger, STRATAFIX, STRAVIX, SURGICEL NU-KNIT, SYMPHONY CATHETER, Serrantor, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, TREO ABDOMINAL STENT-GRAFT SYSTEM, Torus Stent Graft System, V.A.C. VERAFLO CLEANSE CHOICE, VASHE WOUND SOLUTION 250 ML (8.5 FL OZ) FLIP TOP CAP, VISTASEAL | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error